Abstract
BackgroundSimple, robust and clinically meaningful outcome measures are required for neuroprotective trials in Parkinson's disease (PD). We explored the feasibility of using a new composite binary outcome measure of ‘dead...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have